Post-traumatic Stress Disorder Market to Register Incremental Growth During the Forecast Period | Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics

Post-traumatic Stress Disorder Market to Register Incremental Growth During the Forecast Period | Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics
Post-traumatic Stress Disorder Market
As per DelveInsight, the Post-Traumatic Stress Disorder (PTSD) therapeutics market was USD 1,740.2 million in 2021, which is expected to grow by 2032. The market is expected to grow owing to the increase in the prevalence of PTSD, increased initiatives to create public awareness and knowledge of the disease, and the launch of emerging therapies.

Some of the key companies, such as Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, and others, are actively working in the PTSD therapeutics market.

DelveInsight’s “Post-Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Post-Traumatic Stress Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Post-Traumatic Stress Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Post-traumatic Stress Disorder Key Highlights

  • The total market size of post-traumatic stress disorder in the 7MM is approximately USD 1,760 million in 2023 and is projected to increase during the forecast period (2024–2034).
  • In the 7MM, the total 12-month prevalent cases of PTSD were around 13.8 Million in 2023 and are projected to increase during the forecasted period.
  • Post-traumatic stress disorder (PTSD) is a recognized clinical phenomenon characterized by the complex somatic, cognitive, affective, and behavioral effects of psychological trauma, often stemming from exposure to severe stressors like combat, natural disasters, or other traumatic events.
  • Among the 7MM, the US accounted for the highest number of 12-month prevalent cases of Post-traumatic stress disorder (~9,700,000) with ~37% of severe cases.
  • Post-traumatic stress disorder cases are majorly seen among women than men, affecting ~67% of females in the US. The higher prevalence of PTSD among women is likely multifactorial, involving a complex interplay of biological, social, and psychological factors.
  • More than 60% of the post-traumatic stress disorder patient population remain undiagnosed owing to delayed or misdiagnosis, and not so effective diagnostic criteria posing a challenge in seeking treatment.
  • For the last two decades, only two drugs (sertraline and paroxetine) have been approved by the FDA for the treatment of post-traumatic stress disorder.
  • Off-label drug classes such as antidepressants, benzodiazepines, antipsychotics, anticonvulsants, and others have been widely used for the treatment of post-traumatic stress disorder owing to the limited availability of FDA approved treatment options.
  • Antidepressants and antipsychotic drugs represent the largest market segment for Post-traumatic stress disorder therapies in the United States.
  • Among emerging classes, brexpiprazole + sertraline (Otsuka Pharmaceutical), BNC210 (Bionomics), and others will be expanding the treatment landscape of post-traumatic stress disorder.
  • In April 2024, Otsuka and Lundbeck submitted for FDA review of brexpiprazole and sertraline combination as a potential treatment for PTSD.
  • The market size of Post-traumatic stress disorder in the seven major markets was around USD 1800 million in 2023. The market is anticipated to witness a substantial positive shift owing to a better pipeline.
  • The United States accounts for the largest market size (around USD 1600 million) of Post-traumatic stress disorder, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Post-Traumatic Stress Disorder Overview

Post-traumatic stress disorder (PTSD) has been described as “the complex somatic, cognitive, affective, and behavioral effects of psychological trauma.” It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of trauma reminders, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.

PTSD symptoms may start within 1 month of a traumatic event, but sometimes symptoms may not appear for years after. These symptoms cause significant problems in social or work situations and relationships. They can also interfere with the ability to go about the normal daily tasks, and the symptoms are generally grouped into four types: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactions. Symptoms can vary over time or vary from person to person. Patients can develop PTSD when they go through, see, or learn about an event involving actual or threatened death or serious injury.

Post-Traumatic Stress Disorder Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Post-Traumatic Stress Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Post-Traumatic Stress Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Post-Traumatic Stress Disorder Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Post-Traumatic Stress Disorder (PTSD) Epidemiology, Segmented by-

  • Total Treated cases of PTSD in the 7MM

  • Prevalence population of PTSD in the 7MM

  • Diagnosed prevalent Cases of PTSD in the 7MM

  • Severity-specific Cases of PTSD in the 7MM

  • Gender-specific Cases of PTSD in the 7MM

  • Age-specific Cases of PTSD in the 7MM

Post-Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Traumatic Stress Disorder market or expected to be launched during the study period. The analysis covers the Post-Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-Traumatic Stress Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Post-Traumatic Stress Disorder Market Will Evolve and Grow by 2034 @

Post-Traumatic Stress Disorder Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Post-traumatic stress disorders. Currently, Otsuka Pharmaceutical Development & Commercialization is leading the therapeutics market with its Post-traumatic stress disorders drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Include:

  • Alto Neuroscience

  • Aptinyx

  • AstraZeneca

  • Bionomics Limited

  • Boehringer Ingelheim

  • GlaxoSmithKline

  • H. Lundbeck A/S

  • Jazz Pharmaceuticals

  • Nobilis Therapeutics

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

  • Pfizer

  • Remedy

  • Sage Therapeutics

  • Tonix Pharmaceuticals, Inc.

  • Yale University

And Many More

Post-Traumatic Stress Disorder (PTSD) Therapies Covered in the Report Include:

  • NBTX-001 Xenon Inhaler: Nobilis Therapeutics

  • Lu AG06466: H. Lundbeck A/S 

  • JZP150: Jazz Pharmaceuticals

  • NYX-783: Aptinyx

  • BNC210: Bionomics Limited

  • Brexpiprazole:  Otsuka Pharmaceutical Development & Commercialization

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Contents

1. Key Insights

2. Executive Summary 

3. Post-Traumatic Stress Disorder Competitive Intelligence Analysis

4. Post-Traumatic Stress Disorder Market Overview at a Glance

5. Post-Traumatic Stress Disorder Disease Background and Overview

6. Post-Traumatic Stress Disorder Patient Journey

7. Post-Traumatic Stress Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Post-Traumatic Stress Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Post-Traumatic Stress Disorder Unmet Needs

10. Key Endpoints of Post-Traumatic Stress Disorder Treatment

11. Post-Traumatic Stress Disorder Marketed Products

12. Post-Traumatic Stress Disorder Emerging Drugs and Latest Therapeutic Advances

13. Post-Traumatic Stress Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Post-Traumatic Stress Disorder Market Outlook (In US, EU5, and Japan)

16. Post-Traumatic Stress Disorder Access and Reimbursement Overview

17. KOL Views on the Post-Traumatic Stress Disorder Market

18. Post-Traumatic Stress Disorder Market Drivers

19. Post-Traumatic Stress Disorder Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Learn More About the Key Offerings of the Report @

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States